In patients with neovascular age-related macular degeneration (AMD), aflibercept and ranibizumab achieve similar average visual acuity increases, according Australian researchers, as reported by Reuters.
In a January 24 online paper in JAMA Ophthalmology, Dr. Mark C. Gillies of Sydney Hospital and colleagues report on a preplanned one-year interim analysis of the RIVAL randomized trial, which is comparing the two drugs in 281 treatment-naive eyes from 281 participants with active choroidal neovascularization secondary to nAMD and a visual acuity letter score of 23 or greater.
Patients received intravitreal injections of 0.5 mg of ranibizumab or 2.0 mg of aflibercept. Following three injections, they moved on to a treat and extend injection regimen. The primary end-point of the study – the mean change in area of macular atrophy from baseline to study completion at 24 months – is yet to be analyzed.